Skip to search formSkip to main contentSkip to account menu

Adenosine-A2A Receptor Antagonist CPI-444

Known as: Adenosine-A2A Receptor-Targeting Agent CPI-444, CPI-444 
A small molecule immune checkpoint inhibitor of the adenosine A2A receptor (ADORA2A) with potential antineoplastic activity. Upon oral administration… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Go-ahead for first anti-IL-23 mAb to treat psoriasis
2017
2017
Vertex CF data wow Wall Street
2016
2016
Phase 1/1b multicenter trial of the adenosine A2a receptor antagonist (A2aR) CPI-444 as single agent and in combination with atezolizumab (ATZ) in patients(Pts) with advanced cancers
Background: Adenosine is an extracellular signaling molecule thatincreases in response to acute tissue injury/inflammation to… 
2016
2016
Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies
Elevated extracellular adenosine in the tumor microenvironment generates an immunosuppressive niche that promotes tumor growth… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)